Market Overview

Vetr Crowd: After A Large Decline, Regeneron Could Surge 15.5%

Share:

Like most biopharmaceuticals, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has had a tough 2016. Since the year started, the stock has lost about 31.5 percent of its value. Moreover, in the past five trading sessions, shares tumbled more than 7 percent.

Following the most recent decline, the Vetr crowd seems to believe some extra room for upside has been unlocked, as evidenced by its average price target of $429.65, which implies a potential return of roughly 15.5 percent from current valuations.

Related Link: Here's How Crowdsourced Ratings Can Beat The Market

Seeking to better reflect this upside potential, the Vetr community decided upgrade its rating on shares of Regeneron on Friday, from 4.0 Stars (Buy) to 4.5 Stars (Strong Buy) - out of a possible 5.0 Stars rating.

Finally, it should be noted that, in accordance with the rating, 93 percent of the crowd’s ratings are bullish.

Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.

Latest Ratings for REGN

DateFirmActionFromTo
Jun 2019DowngradesBuyHold
May 2019MaintainsNeutral
May 2019Initiates Coverage OnNeutral

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: VetrBiotech Upgrades Health Care Price Target Crowdsourcing Analyst Ratings General

 

Related Articles (REGN)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
SKXMaintains44.0
HYMaintains66.0
MSFTMaintains160.0
SKXUpgrades
WLTWMaintains208.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Qualcomm Now A Buy, Vetr Crowd Says

Bloomberg's Auto Expert Talks About Tesla's Latest Controversy